Detalhe da pesquisa
1.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
N Engl J Med
; 388(18): 1645-1656, 2023 May 04.
Artigo
Inglês
| MEDLINE | ID: mdl-37133584
2.
Evaluation of an Early Individualized Integrated Rehabilitation Program versus Standard Rehabilitation Program for Smoking Cessation in 115 Smokers Among 467 Female Breast Cancer Patients 2019-2021 in Slovenia.
Med Sci Monit
; 29: e942272, 2023 Dec 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38041401
3.
Axillary ultrasound for predicting response to neoadjuvant treatment in breast cancer patients-a single institution experience.
World J Surg Oncol
; 21(1): 292, 2023 Sep 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37715188
4.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat
; 189(3): 689-699, 2021 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-34414532
5.
Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer.
Radiol Oncol
; 52(2): 204-212, 2018 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-30018525
6.
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat
; 191(1): 223-224, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34625861
7.
Symptoms of Anxiety and Depression Among Slovenian Breast Cancer Survivors Post-Treatment During the COVID-19 Pandemic: A Cross-Sectional Study.
Zdr Varst
; 63(1): 55-62, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38156338
8.
Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer.
Breast
; 69: 481-490, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36740512
9.
Intraoperative Touch Imprint Cytology in Breast Cancer Patients After Neoadjuvant Chemotherapy.
Clin Breast Cancer
; 22(4): e597-e603, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35086763
10.
The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.
Clin Breast Cancer
; 22(3): 223-234, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34844889
11.
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Radiol Oncol
; 56(2): 238-247, 2022 05 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35575587
12.
Factors associated with a high level of unmet needs and their prevalence in the breast cancer survivors 1-5 years after post local treatment and (neo)adjuvant chemotherapy during the COVID-19: A cross-sectional study.
Front Psychol
; 13: 969918, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36262447
13.
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
Cancers (Basel)
; 14(7)2022 Mar 22.
Artigo
Inglês
| MEDLINE | ID: mdl-35406370
14.
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Onkologie
; 34(5): 233-8, 2011.
Artigo
Inglês
| MEDLINE | ID: mdl-21577028
15.
Report on isoelectric focusing trial of erythropoietin profiling in two cancer patients during chemotherapy and darbepoetin treatment.
Acta Chim Slov
; 58(1): 139-43, 2011 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-24061954
16.
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
Breast
; 59: 327-338, 2021 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-34390999
17.
High levels of uPA and PAI-1 predict a good response to anthracyclines.
Breast Cancer Res Treat
; 121(3): 615-24, 2010 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-20039121
18.
Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment.
Cancers (Basel)
; 12(3)2020 Feb 25.
Artigo
Inglês
| MEDLINE | ID: mdl-32106399
19.
Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer - results from a real-world setting.
Cancer Treat Res Commun
; 25: 100201, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32979704
20.
Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial.
Cancers (Basel)
; 12(12)2020 Nov 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33255658